Merck’s SpringWorks Therapeutics gains European approval for Ogsiveo
The drug is the first treatment for desmoid tumours to be approved in the region.
List view / Grid view
The drug is the first treatment for desmoid tumours to be approved in the region.
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.